Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (abre nova janela)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexado‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (abre nova janela)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (abre nova janela)

Banan M.

Fonte‎: Ann Hematol 2013;92(3):289-99.

Indexado‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (abre nova janela)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (abre nova janela)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indexado‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (abre nova janela)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (abre nova janela)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Fonte‎: Blood 1996;87(3):887-92.

Indexado‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (abre nova janela)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (abre nova janela)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexado‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (abre nova janela)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (abre nova janela)

Karimi M, Cohan N, Pishdad P.

Fonte‎: Hematology 2015;20(1):53-7.

Indexado‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (abre nova janela)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (abre nova janela)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indexado‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (abre nova janela)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (abre nova janela)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Fonte‎: Hemoglobin 2014;38(2):115-8.

Indexado‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (abre nova janela)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (abre nova janela)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Fonte‎: Blood 2013;121(12):2199-212.

Indexado‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (abre nova janela)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (abre nova janela)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fonte‎: Sci Rep. 2022;12(1):2752.

Indexado‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (abre nova janela)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (abre nova janela)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indexado‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (abre nova janela)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (abre nova janela)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indexado‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (abre nova janela)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (abre nova janela)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Fonte‎: Eur J Haematol 1996;56(5):326-8.

Indexado‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (abre nova janela)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (abre nova janela)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Fonte‎: J Matern Fetal Med 1999;8(1):1-7.

Indexado‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (abre nova janela)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre nova janela)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Indexado‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre nova janela)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (abre nova janela)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Fonte‎: Ann Hematol 2001;80(8):492-5.

Indexado‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (abre nova janela)

Fetal globin induction--can it cure beta thalassemia? (abre nova janela)

Perrine SP.

Fonte‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Indexado‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (abre nova janela)